Background
The recently conducted STRONG-HF trial showed that a high-intensity care (HIC) strategy, consisting of rapid uptitration of guideline-recommended medical therapy (GRMT) and close follow-up, was associated with better outcomes after hospital admission for acute HF (AHF) compared with usual care [1-3]. In the prespecified subgroup analysis, there was a trend towards a larger benefit of HIC over usual care in patients with NT-proBNP levels above the median, although there was no significant interaction [1 ].
Aim of the study
Using data from the STRONG-HF trial, the authors examined the relation of baseline NT-proBNP levels with the efficacy of HIC versus usual care in hospitalized AHF patients and the prognostic significance of changes in NT-proBNP levels during follow-up in the HIC group.
Methods
The STRONG-HF (Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) trial was a multicenter, open-label RCT in which 1078 patients hospitalized for AHF were enrolled who showed high NT-proBNP levels (>2500 pg/mL) at screening and a >10% decrease between screening and randomization (with NT-proBNP >1500 pg/mL before discharge). Within 2 days before the anticipated discharge date, participants were randomized to HIC or usual care.
Patients in the HIC group had follow-up visits at 1, 2, 3, and 6 weeks after randomization. In this group, oral doses of ACEi/ARB/ARNI, beta-blocker, and MRA were rapidly uptitrated to full optimal doses at week 2 if measures, including an NT-proBNP change, indicated it was safe to do so. In patients with an NT-proBNP increase >10% relative to the predischarge level, physicians were advised to consider increasing loop diuretic doses and not uptitrating beta-blockers. Baseline NT-proBNP concentrations were available for 1077 patients and follow-up data for 1007.
Outcomes
The primary endpoint was a composite outcome of all-cause mortality or first HF rehospitalization at 180 days. Secondary endpoints included, among others, all-cause mortality at 180 days.
Baseline NT-proBNP
Change in NT-proBNP during follow-up
In this analysis of the STRONG-HF trial, HIC reduced the rate of all-cause mortality or HF rehospitalization at 180 days (i.e., primary endpoint) in AHF patients compared with usual care, regardless of baseline NT-proBNP levels. In the HIC group, patients who showed increased NT-proBNP levels between randomization and 1 week thereafter were less likely to receive >50% GRMT target doses and were on higher loop diuretic doses compared with those with an NT-proBNP decrease. The early postdischarge NT-proBNP change was associated with a poorer outcome up at 60 and 90 days but not at 180 days.
The authors state the following: “Our analysis suggest[s] a new role for NT-proBNP measurements in the context of rapid uptitration of GRMT as they can alert the physician that the patient has persistent congestion and is not tolerating rapid GRMT uptitration [well], so that beta-blocker titration must be slowed or interrupted and/or higher diuretic doses must be administered.”
1. Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, et al. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail 2019;21:1459–1467. https://doi.org/10.1002/ejhf.1575
2. Cotter G, Davison B, Metra M, Sliwa K, Voors AA, Addad F, et al. Amended STRONG-HF study design. Eur J Heart Fail 2021;23:1981–1982. https://doi.org/10.1002/ejhf.2348
3. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1
Facebook Comments